first approval for ceftobiprole medocaril in europe

1
Inpharma 1665 - 22 Nov 2008 First approval for ceftobiprole medocaril in Europe. Swissmedic has approved ceftobiprole medocaril [Zevtera] as a treatment for complicated skin and skin structure infections, including diabetic foot infections that have not spread to the bone. Basilea Pharmaceutica and Janssen-Cilag will market this antibacterial product in Switzerland. The use of ceftobiprole for this indication is under regulatory review in the US, Australia, and the EU, among other countries; ceftobiprole [as Zeftera] was launched in Canada in August 2008. Janssen-Cilag. New Antibiotic Against Serious Infections - Receives First Approval in Europe. Media Release : 13 Nov 2008. Available from: URL: http://www.janssen-cilag.com 809095370 1 Inpharma 22 Nov 2008 No. 1665 1173-8324/10/1665-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Post on 12-Dec-2016

213 views

Category:

Documents


0 download

TRANSCRIPT

Inpharma 1665 - 22 Nov 2008

■ First approval for ceftobiprole medocaril inEurope. Swissmedic has approved ceftobiprolemedocaril [Zevtera] as a treatment for complicatedskin and skin structure infections, including diabeticfoot infections that have not spread to the bone.Basilea Pharmaceutica and Janssen-Cilag will marketthis antibacterial product in Switzerland. The use ofceftobiprole for this indication is under regulatoryreview in the US, Australia, and the EU, among othercountries; ceftobiprole [as Zeftera] was launched inCanada in August 2008.Janssen-Cilag. New Antibiotic Against Serious Infections - Receives FirstApproval in Europe. Media Release : 13 Nov 2008. Available from: URL:http://www.janssen-cilag.com 809095370

1

Inpharma 22 Nov 2008 No. 16651173-8324/10/1665-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved